Medication info

Posten Injection (Dihydrogen Phosphate Potassium)

Prescription medicationInjection
Ingredient · strength
Monobasic Potassium Phosphate›136.1mg / 1mL
Manufacturer / importer
JW Pharmaceutical Corporation
Appearance
A colorless and transparent injection solution contained in a colorless and transparent vial or ampule.
Packaging
20ml/ampule X 50
Approval status
Active

MFDS item code 199900207 · Notified 1999.07.16 · Insurance code 644904253

Summary

Main use
Treatment of hypophosphatemia accompanied by potassium deficiency
Who receives it
Adults · Children
Adult administration
Determine the dose for each patient according to fluid and electrolyte status and acid-base balance. Monitor blood concentrations and administer at a maximum rate of 20mmol of potassium per hour. For adults receiving total parenteral nutrition (TPN), administer 12~15mmol of phosphorus diluted in 500mL of 50% dextrose injection.
Child administration
For children receiving total parenteral nutrition (TPN), administer 1.5~2mmol per kg of body weight per day diluted in 500mL of 50% dextrose injection.

Ingredients

Manufacturer
JW Pharmaceutical Corporation

Efficacy & effects

Treatment of hypophosphatemia accompanied by potassium deficiency

  • Potassium deficiency
  • hypophosphatemia
View approved original text

This medication is used to improve the symptoms of hypophosphatemia associated with potassium deficiency.

How it is given

Adult administration

Determine the dose for each patient according to fluid and electrolyte status and acid-base balance. Monitor blood concentrations and administer at a maximum rate of 20mmol of potassium per hour. For adults receiving total parenteral nutrition (TPN), administer 12~15mmol of phosphorus diluted in 500mL of 50% dextrose injection.

Child administration

For children receiving total parenteral nutrition (TPN), administer 1.5~2mmol per kg of body weight per day diluted in 500mL of 50% dextrose injection.

Precautions

This drug is provided as an ampule injection and the glass container must be cut carefully. During cutting, glass shards may mix in, so extra caution is needed, especially when used for children or the elderly. This medication should not be administered to patients with certain diseases where hyperkalemia commonly occurs. For instance, dehydration, reduced kidney function, Addison's disease, and patients with weakness and convulsions may be at risk if they use this drug. Also, administration should be avoided in cases of hyperphosphatemia, hypocalcemia, oliguria, anuria, and in patients who already have hyperkalemia. Patients with renal diseases such as renal failure or adrenal insufficiency, those with potassium retention, heart failure patients, and patients with sickle cell anemia should use this drug with caution. This medication may cause phosphorus toxicity and potassium toxicity. Phosphorus toxicity can lower blood calcium levels, leading to muscle spasms or hypocalcemia, while potassium toxicity may cause severe symptoms such as sensory disturbances, muscle weakness, confusion, cardiac arrhythmias, etc. Additionally, gastrointestinal disturbances such as nausea, vomiting, and abdominal pain may occur, so caution is advised. This drug contains phosphorus and potassium, so the total amount of potassium in the fluid must be considered during dosage adjustments. Increased dosing of potassium phosphate may require the addition of calcium, so calcium should be provided separately. When administering to patients with renal failure or adrenal insufficiency, the risk of potassium toxicity is higher, so extra caution is needed. This drug may reduce the effects of cardiac glycosides, and concomitant use with drugs such as aldosterone antagonists, potassium-sparing diuretics, and ACE inhibitors may decrease renal potassium excretion, leading to dangerously elevated potassium levels. Caution is also needed when used alongside nephrotoxic medications such as nonsteroidal anti-inflammatory drugs or some antibiotics, and the risk of gastrointestinal disturbances may increase when used with anticholinergic agents. The safety of this drug during pregnancy has not been fully established, so it should only be used when the benefits of treatment exceed the risks. In cases of overdose, symptoms of phosphorus and potassium toxicity may occur, requiring immediate cessation of administration and appropriate treatment to replenish blood calcium and lower phosphorus and potassium levels. This drug should not be mixed with calcium preparations as it may cause precipitation, and it should be diluted and infused slowly before administration. Any remaining medication after use should be discarded, and careful management is required to prevent phosphorus and potassium toxicity.

Side effects

hypocalcemia, tetany, peripheral neuropathy, muscle weakness, paralysis, lethargy, confusion, leg pressure sensation, fatigue, hypotension, deep vein thrombosis, heart block, loss of P wave, dispersion and duplication of QRS complex, cardiac arrest, nausea, vomiting, abdominal pain

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to avoid contact with air, ideally in a cool place between 15 to 30 degrees Celsius. This way, the effectiveness of the medication can be maintained.

Appearance and packaging

Appearance

A colorless and transparent injection solution contained in a colorless and transparent vial or ampule.

Package unit

20ml/ampule X 50

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.